1,853 material Form 8-K filings that 1,500 companies we cover made with the SEC in September 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Indaptus Therapeutics agreed on September 8, 2026 to sell 20,338,974 shares of common stock to purchasers in a private placement for aggregate gross proceeds of about $24.0 million before offering expenses. The company plans to use the proceeds for working capital, research and development, and general corporate purposes, possibly including early-stage work on a neurotechnology device for sleep-related conditions. The shares are unregistered, and the company must later file a resale registration statement, which could add shares to the market.
Shares sold: 20,338,974 shares of common stock at a price equal to the Nasdaq Minimum Price plus $0.015 per share
Gross proceeds: approximately $24.0 million before offering expenses
Closing: subject to customary conditions, no later than the fifteenth business day after September 8, 2026
Shares were sold under Section 4(a)(2) and/or Regulation S and are subject to transfer restrictions
Group 1 Automotive agreed to sell $1.25 billion of senior unsecured notes in two tranches, due 2032 and 2035, with expected net proceeds of about $1,236.0 million and closing expected on September 22, 2026. The company plans to use the proceeds, with cash on hand, to fund its pending purchase of dealership assets and related real estate from Hennessy Automobile Companies, and the filing says the 2032 notes must be redeemed if that acquisition is not completed by the outside date.
$625.0 million of 6.250% senior notes due 2032 and $625.0 million of 6.625% senior notes due 2035, sold at par
Expected net proceeds of approximately $1,236.0 million; closing expected September 22, 2026
If the Hennessy Acquisition is not consummated by January 6, 2027, or any extended date, the 2032 notes must be redeemed at 100% of issue price plus accrued interest
Affiliates of certain initial purchasers are lenders under the company's revolving credit facility and will receive a portion of the net proceeds
PAVmed Inc. signed a Sales Agreement with A.G.P./Alliance Global Partners that lets it sell common stock through the agent from time to time, up to $9,400,000 of shares under its current prospectus supplement. The company says it plans to use net proceeds for working capital and general corporate purposes, and the sales would dilute existing shareholders.
Maximum offering under the current prospectus supplement is $9,400,000 of common stock.
The agent's commission is 3.0% of aggregate gross sales prices, plus legal cost reimbursements of up to $65,000 at signing.
Shares are offered under a Form S-3 shelf registration declared effective April 15, 2025, with a prospectus supplement dated September 9, 2026.
Either party may terminate the agreement on ten business days' written notice.
Plains All American Pipeline priced $700 million of 6.75% Series A and $800 million of 7.00% Series B junior subordinated notes due 2056, expected to close September 14, 2026. The company plans to use the proceeds, with cash on hand and commercial paper, to redeem all of its outstanding Series A and Series B preferred units. The filing replaces preferred units with junior debt but does not state the effect on earnings or distributions.
$700 million of 6.75% Series A and $800 million of 7.00% Series B junior subordinated notes due 2056 priced, with closing expected September 14, 2026
Proceeds, cash on hand and commercial paper to redeem all 58,411,908 Series A preferred units and all 800,000 Series B preferred units
Series A units redeemed at $28.875 per unit (110% of $26.25 par) on or about September 14, 2026; Series B at $1,000 par on or about October 9, 2026
STAAR Surgical appointed David Bailey, its former President and Chief Executive Officer, as Chief Commercial Officer effective September 8, 2026. He reports to CEO Warren Foust, and the filing sets out his base salary, bonus target and equity awards, which shareholders can review in the offer letter filed as Exhibit 10.1.
Appointed Chief Commercial Officer effective September 8, 2026; reports to Warren Foust, President and CEO
Base salary at an annual rate of CHF 462,825 (approximately $575,000), with a 2026 target bonus of 60% of base salary, prorated
Initial RSU grant valued at $850,000 vesting over three years, plus a 2026 long-term incentive award valued at $1,400,000, prorated
Mr. Bailey previously served as STAAR's President and CEO from 2001 to 2008 and as President, International Operations, from 2008 to 2011
Enbridge agreed with an underwriting syndicate led by RBC Capital Markets and CIBC Capital Markets to sell 38.9 million common shares at CDN$66.85 each, for gross proceeds of CDN$2.6 billion. The company plans to use the net proceeds to partially fund announced acquisitions and to create financial flexibility for future growth, which would add new shares outstanding for existing holders.
Offering of 38,900,000 common shares at CDN$66.85 per share, for aggregate gross proceeds of CDN$2.6 billion
Offering expected to close on or about September 14, 2026
Underwriters hold an option for up to 15% more shares, which would bring gross proceeds to about CDN$3.0 billion if fully exercised
Net proceeds intended to partially fund announced acquisitions and provide financial flexibility
Wrap Technologies amended the employment agreements of Chief Executive Officer Scot Cohen and President and Chief Operating Officer Jared Novick and approved performance restricted stock grants to each on September 2, 2026. The awards total 6,000,000 shares and vest only if the company's market capitalization meets thresholds from $150.0 million to $506.25 million, with part of the shares also tied to a stockholder vote to increase the equity plan's authorized shares. The filing also extends the post-termination exercise period on certain prior stock options from three months to 24 months.
Scot Cohen receives 4,000,000 performance restricted stock shares; Jared Novick receives 2,000,000, approved September 2, 2026.
Shares vest in tranches when market capitalization meets $150.0 million, $225.0 million, $337.5 million and $506.25 million for 45 consecutive trading days.
1,600,000 Cohen shares and 800,000 Novick shares are void if stockholders do not approve an equity plan increase by March 15, 2027.
Both employment agreements set a $200,000 annualized base salary and a two-year initial term, with 12-month automatic renewals.
Diversified Energy Company agreed on September 2, 2026 to acquire Birch Permian Holdings and related companies in a transaction with an aggregate purchase price of approximately $1.8 billion, including repayment of indebtedness. The deal adds about 46,000 net mineral acres in the Midland Basin plus midstream and water infrastructure, and is expected to close in the fourth quarter of 2026 subject to customary conditions. The company expects to fund roughly $1.5 billion through an asset-backed securitization, with the remainder from other sources including its revolving credit facility.
Aggregate purchase price of approximately $1.8 billion, subject to adjustments
Expected funding includes an asset-backed securitization of approximately $1.5 billion before closing
Merger Agreement requires a $50 million deposit; a $50 million termination fee applies in certain cases
Expected closing in the fourth quarter of 2026, subject to customary closing conditions
Culp reported first-quarter fiscal 2027 results for the period ended August 2, 2026, with net sales of $54.0 million, up 6.5% from a year earlier, and net income of $6.0 million, or $0.47 per diluted share, versus a net loss of $231 thousand a year earlier. Reported profit includes $6.9 million in tariff refunds, and excluding them the company shows an adjusted operating loss of $271 thousand, narrower than the $1.9 million adjusted loss a year ago. The company also cut net debt to $3.1 million from $10.9 million at fiscal year-end and expects break-even operating income in the second quarter.
Net sales $54.0 million, up 6.5%; bedding sales up 13.2% to $31.8 million, upholstery down 1.9% to $22.2 million
Net income $6.0 million, or $0.47 per diluted share, including $6.9 million in tariff refunds tied to the Supreme Court's February 2026 IEEPA ruling
Adjusted operating loss of $271 thousand, compared with an adjusted operating loss of $1.9 million a year earlier
Net debt fell to $3.1 million from $10.9 million at fiscal year-end; company expects break-even operating income in the second quarter
CooperCompanies said its strategic review is complete and the Board unanimously decided to retain CooperSurgical, while also expanding its share repurchase authorization from $2 billion to $3 billion. The same day it reported fiscal third-quarter results with revenue up 1% and non-GAAP diluted EPS up 4%, though GAAP EPS was lifted by a $307.2 million tax benefit.
Q3 revenue $1.066 billion, up 1%; non-GAAP diluted EPS $1.15, up 4% from $1.10
GAAP diluted EPS $2.24 versus $0.49, driven by a $307.2 million discrete tax benefit from a U.K. tax examination
Buyback authorization raised from $2 billion to $3 billion; about $1.5 billion remains available after $339.1 million repurchased in the quarter
Fiscal Q4 2026 non-GAAP diluted EPS guidance of $1.05 to $1.09; fiscal 2026 guidance of $4.51 to $4.55
In an investor presentation furnished under Regulation FD, Americold said its key operating metrics rose both year over year and sequentially in July and August 2026. The company closed its joint venture with EQT on August 31, 2026, which generated $1.15 billion of net proceeds used to pay down debt, and it reiterated full-year AFFO guidance of $1.26 to $1.32. For shareholders, the deal is a significant step in reducing leverage, and the company projects about $46 million in annual interest savings.
Occupancy, blended pricing and throughput all increased year over year in July and August, based on preliminary results that are subject to change.
The EQT joint venture closed August 31, 2026, with a total value of about $1.3 billion and a 70% EQT / 30% Americold ownership split.
Full-year AFFO guidance of $1.26 to $1.32 was reiterated, and net debt was about $4 billion at June 30, 2026.
On September 9, 2026, CenterPoint Energy and its subsidiaries Houston Electric, CERC and SIGECO replaced their existing revolving credit facilities with four new five-year facilities totaling $4.6 billion in aggregate commitments. The company reported that no termination penalties were incurred on the earlier facilities. The filing describes a refinancing of existing credit capacity rather than a change in the company's earnings or guidance.
CenterPoint Energy parent replaced its $2.4 billion facility, dated December 6, 2022, with a new $2.2 billion facility, with a request option for increases up to $2.5 billion.
Houston Electric replaced a $300 million facility with a new $1.0 billion facility; CERC replaced $1.05 billion with $1.1 billion; SIGECO replaced $250 million with $300 million.
The parent facility limits debt to consolidated capitalization to 67.5%, temporarily raised to 70% after certain natural disaster certifications.
JPMorgan Chase Bank, N.A. serves as administrative agent for the parent facility and will serve as agent for the other three facilities.
Rallybio's Chief Financial Officer, Jonathan Lieber, will move to part-time employment effective September 15, 2026, but will remain CFO and Principal Financial Officer with the same duties and authority. His employment will end when the pending business combination with Avenzo Therapeutics closes, unless it is terminated earlier.
Part-time transition effective September 15, 2026; he keeps the CFO and principal financial officer titles
Base salary of $420,000 after the transition, with benefit plan participation
No annual bonus for 2026 or any later year he is employed
Employment ends at the closing of the Avenzo merger agreement dated May 31, 2026; severance follows under his existing employment agreements
American Eagle Outfitters reported second-quarter fiscal 2026 results for the period ended August 1, 2026, with net revenue up 8% to $1.38 billion and diluted earnings per share of $0.79 versus $0.45 a year earlier. The quarter included a net $161 million operating benefit from tariff refunds, and the company set fiscal 2026 operating income guidance of $540 million to $550 million that includes that benefit. Aerie comparable sales rose 19% while American Eagle comparable sales fell 1%.
Net revenue of $1.38 billion rose 8%; comparable sales rose 6%, with Aerie up 19% and American Eagle down 1%.
Operating profit was $211 million versus $103 million last year, including a net $161 million tariff refund benefit.
Diluted EPS was $0.79 versus $0.45 last year.
Fiscal 2026 operating income guidance is $540 million to $550 million, inclusive of the net tariff refund benefit; third-quarter operating income is guided to $110 million to $115 million.
Selling stockholders affiliated with TDR Capital agreed to sell 14,000,000 Target Hospitality common shares at $18.50 per share in an underwritten offering, and the company will not receive any of the proceeds. Separately, the company agreed to buy back shares from the underwriters for approximately $30 million, funded with cash on hand and ABL Credit Facility borrowings, with the closing expected on September 10, 2026.
14,000,000 shares offered by Arrow Holdings S.à r.l. and MFA Global S.à r.l. at $18.50 per share, for approximately $259,000,000 in gross proceeds to the selling stockholders
Company will not receive any proceeds from the offering
Company to repurchase shares from the underwriters for approximately $30,000,000, to be held as treasury shares and funded with cash on hand and ABL Credit Facility borrowings
Underwriters have a 30-day option to buy up to 2,100,000 additional shares; closing is expected on September 10, 2026
Enbridge said a wholly-owned subsidiary has signed a definitive agreement to acquire Tallgrass Energy's crude oil transportation, gathering, storage and terminaling business for U.S.$2.55 billion in cash, subject to customary closing adjustments. Enbridge expects the deal to be accretive to distributable cash flow per share in the first full year of ownership, and says its 2026 financial guidance is not materially affected because closing is expected later in 2026.
Cash consideration of U.S.$2.55 billion, representing an estimated acquisition multiple of 10-11x forward enterprise value to EBITDA.
Assets include 75% of Pony Express Pipeline, 51% of Powder River Gateway system, and about 8.4 million barrels of storage across nine crude terminals.
PXP2 expansion of U.S.$0.3 billion is expected to increase Pony Express capacity to about 515 kbpd, with service expected in late 2027.
Closing is expected later in 2026, subject to regulatory approvals including Federal Trade Commission clearance; an equity offering will partially fund the deal.
Kewaunee Scientific reported first-quarter fiscal 2027 sales of $66.3 million, down 6.7% from a year earlier, and diluted earnings per share of $0.58 versus $1.04. Pre-tax earnings fell 34.7%, partly due to extra compensation expense from settling long-term incentive awards in cash, which the company says will not recur. Backlog rose from April 30, 2026 but remained below its level a year earlier.
Sales were $66.3 million versus $71.1 million; net earnings attributable to the company were $1.7 million versus $3.1 million.
Pre-tax earnings were $2.6 million versus $3.9 million, a decrease of 34.7%.
Backlog rose to $169.0 million on July 31, 2026, from $165.9 million on April 30, 2026, but was $205.0 million on July 31, 2025.
Long-term debt excluding the sale-leaseback obligation fell to $13.8 million from $15.1 million on April 30, 2026.
Essential Properties Realty Trust promoted Chief Operating Officer R. Max Jenkins to President and Chief Operating Officer, expanded Robert W. Salisbury's role to include Chief Strategy Officer, and named Craig Vachris Chief Investment Officer after A Joseph Peil's employment ended September 8, 2026. CEO Peter M. Mavoides continues in his role and signed a new employment agreement, which matters to shareholders because it reshapes the senior team that runs investments and strategy.
Jenkins appointed President and Chief Operating Officer; Mavoides remains Chief Executive Officer, with amended employment agreements effective September 8, 2026 running through March 31, 2031
Jenkins and Salisbury received promotion grants of long-term incentive plan units with a target grant date value of $2,000,000, vesting 50% at three and four years
Craig Vachris, with more than 20 years of commercial real estate and net lease experience, named Executive Vice President and Chief Investment Officer
Peil's employment ended September 8, 2026, and he is eligible for severance for a termination without cause
Fortune Brands Innovations appointed Peter G. Clifford as Executive Vice President and Chief Financial Officer, effective September 21, 2026. Interim CFO Ashley George will return to her prior role as Senior Vice President, Finance. The filing also sets out Clifford's pay and inducement equity awards, which are granted outside the company's 2022 Long-Term Incentive Plan.
Clifford, 56, was CFO of Filtration Group Corporation until August 2026.
Base salary of $700,000, annual bonus target of 90% of base salary, and long-term incentive target of $1,950,000.
Inducement awards: performance-based RSUs on 130,000 shares and stock options on 65,000 shares, to be granted September 28, 2026.
Ashley George, Interim CFO, will become Senior Vice President, Finance.
Research Solutions reported fiscal 2026 net income of $2.8 million, or $0.09 per diluted share, up from $1.3 million, or $0.04, a year earlier, while total revenue fell to $48.3 million from $49.1 million. Fourth-quarter revenue of $12.1 million and net income of $666,000 were both below the prior-year quarter, which included a $1.1 million favorable Scite earnout adjustment, so shareholders see a mixed picture of annual profit growth alongside shrinking sales.
Fiscal 2026 net income was $2.8 million, or $0.09 per diluted share, versus $1.3 million, or $0.04, in fiscal 2025.
Fiscal 2026 total revenue was $48.3 million versus $49.1 million; transaction revenue fell to $27.5 million from $30.1 million.
Fourth-quarter net income was $666,000, or $0.02 per diluted share, versus $2.4 million, which included a $1.1 million Scite earnout adjustment.
B2B ARR rose 14.1% to $16.2 million, and total ARR rose 7.8% to $22.5 million as of June 30, 2026.
Luxfer Holdings said the U.S. Hart-Scott-Rodino waiting period for its proposed acquisition by Double Eagle Acquisition Buyer, Inc., a holding company owned by funds managed by Wynnchurch Capital, expired at 11:59 p.m. EDT on September 8, 2026. That clears one of the closing conditions, but the deal still requires shareholder approval, certain other regulatory approvals and High Court sanction in England and Wales.
HSR waiting period expired at 11:59 p.m. EDT on September 8, 2026.
The transaction is a scheme of arrangement under Part 26 of the U.K. Companies Act 2006, under a Transaction Agreement dated July 26, 2026.
Remaining conditions include shareholder approval and certain other regulatory approvals.
A preliminary proxy statement was filed with the SEC on August 26, 2026.
Lakeland Industries reported fiscal second quarter 2027 results for the period ended July 31, 2026. Net sales fell 4.5% year over year to $50.1 million, and the company posted a net loss of $4.9 million, compared with net income of $0.8 million a year earlier. The loss included a non-cash goodwill impairment of approximately $3.2 million tied to LHD Germany, partly offset by a $1.9 million gain on lease settlement.
Net sales were $50.1 million versus $52.5 million in Q2 FY26, a decrease of 4.5%; gross margin was 37.0% versus 35.9%.
Net loss was $4.9 million, or $0.50 per share, versus net income of $0.8 million, or $0.08 per share, in Q2 FY26.
Adjusted EBITDA was $1.4 million versus $5.0 million a year earlier; adjusted EBITDA excluding FX was $2.7 million versus $5.1 million.
As of July 31, 2026, the company had $24.9 million outstanding under its revolving credit facility and was in compliance with its debt covenants.
Navan reported second-quarter fiscal 2027 results for the quarter ended July 31, 2026, with revenue up 35% year-over-year to $233 million. It raised its fiscal 2027 total revenue outlook to $927 million to $933 million, while its GAAP loss from operations widened to $26 million from $12 million a year earlier. Shareholders get higher revenue and guidance, though the GAAP operating loss grew and the GAAP net loss narrowed to $29 million from $39 million.
Q2 GAAP net loss was $29 million, compared with $39 million in the year-earlier quarter; non-GAAP net income was $14 million, compared with a non-GAAP net loss of $8 million.
Fiscal 2027 total revenue outlook raised to $927 million to $933 million; non-GAAP income from operations expected at $82 million to $86 million.
Third-quarter fiscal 2027 total revenue expected at $253 million to $255 million.
Navan acquired Smartrips, a Brazilian travel management company, and BoomPop, an AI-native meetings and events platform.
8x8 posted an investor presentation on September 9, 2026, with first-quarter fiscal 2027 results and fiscal 2027 guidance given as of August 4, 2026. Revenue rose to a record, but the company's own guidance implies lower non-GAAP operating margin and operating profit for fiscal 2027 than fiscal 2026, and the term loan is due in August 2027.
Q1 fiscal 2027 total revenue of $190M, up 4.9% year over year; GAAP operating margin 2.3% and non-GAAP operating margin 9.9%.
Aviat Networks disclosed that on September 2, 2026, its subsidiary Aviat U.S., Inc. received orders from an existing North America customer worth $35 million to $40 million. The company said future deployment timing, scale and scope remain subject to the customer's internal planning and market conditions, so the orders do not guarantee the full amount will be realized as revenue on a fixed schedule.
Orders of $35 million to $40 million received September 2, 2026 by subsidiary Aviat U.S., Inc.
Customer is an existing North America customer; the filing does not name it.
Future deployments depend on the customer's internal planning and market conditions.
Filed under Regulation FD (Item 8.01, Other Events) on September 9, 2026, signed by CFO Andrew C. Schmidt.
At an extraordinary general meeting on September 8, 2026, shareholders approved extending Andretti Acquisition Corp. II's deadline to complete a business combination from September 9, 2026 to September 9, 2027, or an earlier date set by the board. Holders of 15,776,190 Public Shares redeemed them for cash, an aggregate of approximately $171.69 million, leaving 7,223,810 Public Shares outstanding.
Extension Amendment vote: 23,241,840 for, 2,775,781 against, 0 abstentions
Meeting Redemptions: 15,776,190 Public Shares at approximately $10.88 per share, about $171.69 million in total
On September 8, 2026, the Company and Sponsor signed a new non-redemption agreement covering up to 650,000 Non-Redeemed Shares
Sponsor converted 5,749,999 Class B shares into Class A; after the conversion and redemptions there are 13,733,809 Class A and one Class B ordinary share outstanding
Gloo Holdings reported second-quarter results for the three months ended July 31, 2026, with revenue of $46.6 million, up from $16.2 million a year earlier, and a net loss of $21.2 million, narrowed from $44.1 million. The company raised its fiscal 2026 revenue guidance to $200 million and reiterated that it expects Adjusted EBITDA profitability in the fourth quarter of 2026, which points to improving results for shareholders while losses remain.
Q2 2026 revenue was $46.6 million, up 188% from $16.2 million, and above guidance of $44.0 million.
Net loss narrowed to $21.2 million from $44.1 million; Adjusted EBITDA was negative $8.3 million, versus guidance of negative $8.5 million.
Fiscal 2026 revenue guidance raised to $200 million; third-quarter revenue expected at $55 million and Adjusted EBITDA at negative $3.5 million.
Cash and cash equivalents were $39.3 million at July 31, 2026, down from $57.3 million at January 31, 2026.
Wealthfront reported fiscal second quarter 2027 results for the period ended July 31, 2026. Revenue rose 1% year-over-year to $91.9 million, but GAAP diluted net income fell 49% to $17.6 million and diluted EPS fell to $0.10 from $0.24, mainly due to higher stock-based compensation tied to awards recognized after the December 2025 IPO. Total Platform Assets grew 12% to $99.0 billion, and the company said it surpassed $100 billion at the end of August.
Total revenue $91.9 million, up 1% from $91.1 million; GAAP net income $17.6 million versus $34.7 million
Stock-based compensation expense $16.4 million versus $1.6 million a year earlier; adjusted EBITDA $38.1 million, down 15%
Total Platform Assets $99.0 billion, up 12%; funded clients 1.51 million, up 14%
Company repurchased 3.3 million shares for approximately $30 million in the quarter
Skillsoft reported second-quarter fiscal 2027 revenue of $98.2 million, down 3% from a year earlier, while its net loss narrowed 17% to $15.0 million. The company lowered its full-year revenue guidance to $380 million-$390 million from $388 million-$406 million, citing pressure in its consumer business, and kept its Adjusted EBITDA and free cash flow guidance unchanged. The Global Knowledge business was sold to Enduring Ventures in July 2026.
Q2 revenue was $98.2 million, down 3% from $101.2 million a year earlier.
Net loss improved to $15.0 million, or $1.67 per share, from $18.0 million, or $2.10 per share.
Full-year fiscal 2027 revenue guidance was cut to $380 million-$390 million; Adjusted EBITDA ($108 million-$116 million) and free cash flow ($14 million-$22 million) guidance were maintained.
Global Knowledge sale to Enduring Ventures was completed in July 2026.
Horizon Funding II, a wholly owned subsidiary of Horizon Technology Finance Corporation (HRZN), signed amendments on September 2, 2026 to its securitization financing documents, including a second supplemental indenture and a second amended and restated note funding agreement. The filing says the amendments extend the Legal Final Payment Date to December 10, 2035, but it does not disclose the size of the notes or any change in interest cost, so the financial effect for shareholders is not quantified.
Amendments dated September 2, 2026 cover the indenture, note funding agreement and sale and servicing agreement for Horizon Funding II, LLC.
The Legal Final Payment Date is extended to December 10, 2035.
The filing references the original indenture dated June 21, 2024 and prior amendments dated May 23, 2025.
The 8-K was signed by CEO Michael P. Balkin on September 9, 2026.
AeroVironment reported first-quarter fiscal 2027 revenue of $480.5 million, up 6% from a year earlier, and a net loss of $5.1 million, or $0.10 per diluted share, versus a $67.4 million loss a year earlier. The company said it continues to expect full-year fiscal 2027 revenue of $2.125 billion to $2.225 billion and non-GAAP adjusted EBITDA of $305 million to $325 million.
Revenue $480.5 million vs. $454.7 million a year earlier; net loss $5.1 million vs. $67.4 million
Non-GAAP adjusted EBITDA $53.4 million vs. $56.6 million; non-GAAP EPS $0.59 vs. $0.32
Funded backlog $1.5 billion as of August 1, 2026, up 37% year over year; bookings $0.7 billion, book-to-bill 1.4
Full-year fiscal 2027 guidance unchanged: revenue $2.125 billion to $2.225 billion, EPS $0.21 to $0.53
Procore Technologies said it completed its merger with DroneDeploy on September 9, 2026, under a merger agreement first announced July 27, 2026. Procore acquired DroneDeploy for an approximate purchase price of $845.0 million in cash, subject to adjustments for working capital, transaction expenses, cash and indebtedness. The filing gives no financial results for either company, so its effect on Procore's earnings is not stated.
Merger completed September 9, 2026; DroneDeploy is now a wholly-owned subsidiary of Procore
Approximate purchase price of $845.0 million in cash, subject to adjustments
Merger agreement originally entered into July 27, 2026, and reported in an 8-K filed July 29, 2026
Limoneira reported fiscal third-quarter 2026 revenue of $43.8 million, down from $47.5 million a year earlier, and a net loss of $0.17 per diluted share versus $0.06. Adjusted EBITDA rose to $3.9 million from $3.0 million, and the company raised its avocado volume guidance while narrowing lemon volume to the lower end of its range. The company also agreed to sell the Windfall Farms property for $15.0 million in cash, with closing expected September 14, 2026.
Q3 total net revenues were $43.8 million, versus $47.5 million, mainly due to the transition of citrus brokerage operations to Sunkist.
Q3 operating loss was $3.0 million, versus $0.6 million; net loss per diluted share was $0.17, versus $0.06.
Adjusted EBITDA was $3.9 million, versus $3.0 million in the prior-year quarter.
Fiscal 2026 avocado volume guidance raised to 7.0 to 7.25 million pounds; lemon volume expected at the lower end of 4.0 to 4.5 million cartons.
SRX Global entered a Limited Consent and Amendment Agreement on September 8, 2026, under which holders of its Series C convertible preferred stock consented to and waived certain rights so the company can maintain a stock repurchase plan. The plan allows repurchases of up to the lesser of 10,000,000 shares or 50% of outstanding common stock, for an aggregate price not to exceed $20,000,000, through July 7, 2027. The filing does not state how much stock the company has bought back or plans to buy back.
Consent Agreement dated September 8, 2026, between the company and the Required Holders of Series C preferred stock
Repurchase plan cap: lesser of 10,000,000 common shares or 50% of outstanding common stock, up to $20,000,000 in aggregate purchase price
Plan period ends July 7, 2027
Related August 27, 2026 sale of 3,579 Series C preferred shares for $2.825 million; the Series C shares are convertible into common stock
CME Group announced senior leadership changes in its finance and legal divisions. Jack Tobin becomes Deputy Chief Financial Officer on November 2, 2026, and Chief Financial Officer in March 2027, when Lynne Fitzpatrick becomes Chief Executive Officer. The changes also bring a new General Counsel, John Marchese, and a new Chief Accounting Officer, Matthew Render, but the filing gives no financial results or figures tied to these appointments.
Jack Tobin becomes Deputy Chief Financial Officer on November 2, 2026, and Chief Financial Officer in March 2027, when Lynne Fitzpatrick becomes Chief Executive Officer.
Matthew Render succeeds Tobin as Managing Director, Chief Accounting Officer effective November 2, 2026, after joining CME Group in August 2026.
John Marchese is promoted to General Counsel, succeeding Jonathan Marcus, who has served as General Counsel since 2022 and is stepping down later this month.
Tobin previously planned to retire effective October 30, 2026, but will now continue with the company.
The New York Times Company said Executive Vice President and Chief Human Resources Officer Jacqueline Welch will step down effective January 1, 2027. The filing says she will be eligible for severance under the company's Executive Severance Plan, subject to a general release and restrictive covenants, and is entitled to payments under long-term performance awards because she meets the retirement requirements.
Jacqueline Welch steps down as Executive Vice President and Chief Human Resources Officer, effective January 1, 2027
Severance eligibility under the Executive Severance Plan is subject to a general release of claims and compliance with restrictive covenants
Welch has met the age and service requirements for Retirement under awards granted under the 2020 Incentive Compensation Plan and is entitled to payments under those awards
On September 7, 2026, Lexaria Bioscience Corp. agreed with holders of existing warrants covering 453,969 shares to exercise them immediately at a reduced $12.92 per share, for expected gross proceeds of about $5.9 million before fees and expenses. In return, the company will issue new unregistered Series A and Series B warrants, each covering 453,969 shares at $12.67, and must file a resale registration statement for the underlying shares. The cash is intended for working capital and general corporate purposes, but the reduced exercise price and new warrants add potential future share issuance for existing shareholders.
Expected gross proceeds of about $5.9 million from the warrant exercises, before placement agent fees and offering expenses; closing expected September 9, 2026.
Existing warrants issued in 2024 and 2025 had original exercise prices from $17.85 to $45.90 per share; holders exercised at $12.92.
New Series A warrants (five-year term) and Series B warrants (18-month term) each cover 453,969 shares at $12.67 per share.
H.C. Wainwright & Co. is placement agent, paid a fee of 7% of gross proceeds, and received warrants for 15,889 shares at $16.15.
Aspire-Lakewood Holdings, Inc. filed a charter amendment changing its name from Aspire Biopharma Holdings, Inc., effective September 8, 2026, and its Board authorized a $10 million common stock repurchase program effective September 9, 2026. The company said the buyback reflects its view that its share price does not reflect its financial strength, and it cited the newly acquired Dura Control Systems Corp. (DCSC) as support.
Board authorized a $10 million common stock repurchase program, effective September 9, 2026, with no expiration date and no required number of shares.
Name change to Aspire-Lakewood Holdings, Inc. was effective September 8, 2026; no stockholder approval was required and the CUSIP is unchanged.
The 8-K states the Nasdaq trading symbol remains ASPB, while the press release uses ASBP.
DCSC reported audited 2025 revenue of approximately $209.5 million and Adjusted EBITDA of $22.3 million; unaudited six months ended June 30, 2026 revenue was approximately $103.9 million and Adjusted EBITDA $10.5 million.
Limbach Holdings and subsidiaries entered a five-year, $300.0 million credit agreement with PNC Bank, National Association, maturing September 9, 2031. The new facility replaces the company's existing $125.0 million Wintrust revolving credit facility, which was terminated after about $118.1 million of principal was repaid from PNC proceeds, with no early termination penalties reported.
Facility totals up to $300.0 million: $200.0 million revolver, $50.0 million term loan and $50.0 million delayed draw term loan
Loans priced at Base Rate plus 0.50% to 1.50%, or Term SOFR plus 1.50% to 2.50%, based on net leverage
Financial covenants require maximum net leverage of 3.00 to 1.00 and minimum fixed charge coverage of 1.15 to 1.00
About $7.0 million of existing letters of credit remain outstanding under the former Wintrust agreement until they expire, with latest expiry in April 2027
On September 9, 2026, MediaAlpha agreed to buy the Tax Receivables Agreement interest of three Parallaxes entities (PLX) for $12.0 million in cash, a $10.7 million (47%) discount to the estimated value as of June 30, 2026. The company estimates its total remaining TRA liability will fall to about $32 million as of September 30, 2026, from $54.7 million as of June 30, 2026, and the deal does not trigger a change of control or early termination.
Cash price of $12.0 million is a $10.7 million, or 47%, discount to the estimated value as of June 30, 2026.
PLX's share of the estimated TRA liability was $22.7 million of the $54.7 million total as of June 30, 2026.
Estimated total remaining TRA liability is about $32 million as of September 30, 2026.
Payment was funded from subsidiary cash; QLH made a pro rata distribution to members, including certain directors and executive officers.
Intelligent Bio Solutions said it submitted a 510(k) premarket notification to the FDA seeking clearance of its Intelligent Fingerprinting Drug Screening System for detecting codeine. The company says the submission is based on a 2026 clinical program and that FDA clearance is expected to expand its addressable U.S. market beyond forensic-use-only settings. The filing does not state a clearance timeline or any financial figures.
Submission announced September 9, 2026 for codeine detection on the Intelligent Fingerprinting Drug Screening System
Method Comparison Study reported accuracy above 98%, sensitivity above 94% and 100% specificity across three U.S. clinical sites
Cybersecurity review reported 100% of medium-risk vulnerabilities remediated and all 19 SBOM vulnerabilities resolved
Filing gives no FDA review timeline and no financial results or guidance
Tenon Medical said it repaid in full its original issue discount senior convertible promissory notes, with an aggregate principal balance of approximately $5.16 million, ahead of their September 11, 2026 maturity date. The company says the repayment removes the potential for the notes to convert into common stock at a discount to market prices, which it describes as reducing potential dilution for shareholders.
Notes with approximately $5.16 million aggregate principal balance repaid in full
Notes were issued on March 11, 2026 and were due September 11, 2026
Company states the repayment reduces potential dilution from discounted conversion into common stock
Genuine Parts Company said board member Court Carruthers has been appointed Chief Executive Officer-Elect, effective September 8, 2026, and will become CEO when the planned separation of its Automotive and Industrial businesses closes. The separation is targeted for the first quarter of 2027, and Will Stengel will remain Chairman and CEO until then before joining Motion as its Chairman and CEO. The changes set the leadership structure for the two standalone companies that shareholders will hold after the separation.
Court Carruthers: CEO-elect effective September 8, 2026, with a base salary of $1,000,000 that rises to $1,200,000 when he becomes CEO at closing
Separation of Automotive and Industrial businesses targeted for the first quarter of 2027
Bert Nappier named Executive Vice President, Chief Operating Officer and Chief Financial Officer, effective September 6, 2026; James Howe named Motion President and Chief Operating Officer
GPC and Motion investor days scheduled for December 8, 2026 and December 9, 2026
On September 8, 2026, Centerspace entered a merger agreement under which Independence Realty Trust (IRT) will acquire it in an all-stock transaction, with each Centerspace common share converted into 3.8 IRT common shares. Closing requires Centerspace and IRT shareholder approvals, an effective Form S-4 registration statement, lender consents, and other conditions, and the agreement can be terminated if the merger is not completed by June 30, 2027. For shareholders, the deal would replace their Centerspace shares with IRT shares, so the value they receive will move with IRT's share price.
Exchange ratio of 3.8 IRT common shares for each Centerspace common share, with cash paid in lieu of fractional shares
Termination fees of $45 million payable by Centerspace and $60 million payable by IRT under specified circumstances
Merger can be terminated if not completed by June 30, 2027; presentation says closing could occur as soon as the end of Q4 2026
Until closing, Centerspace may pay regular quarterly dividends of up to $0.77 per share, then a stub dividend of up to $0.09 per share in the closing quarter
electroCore's board appointed Joshua Lev, its interim president and CFO, and Mike Fox, its COO, as co-Chief Executive Officers and president, effective September 8, 2026. Both will keep their current finance and operations roles and join the board as Class III directors, increasing the board from six to eight members. The filing also shows higher pay for both executives, a revised executive severance policy, and bylaw changes that tighten rules for shareholder director nominations.
Lev and Fox were named co-CEOs and president on September 8, 2026, and will remain CFO and COO, respectively.
Lev's base salary rises from $470,000 to $540,000 with a 50% target bonus; Fox's base salary rises from $505,000 to $540,000 and his target bonus rises from 40% to 50%.
Each received 55,000 restricted stock units vesting in equal annual installments over three years.
The CEO change-in-control severance formula now provides a lump sum at a 1.5x multiple, and the bylaws add stricter advance notice and group disclosure requirements for shareholder nominees.
Definitive Healthcare disclosed that representatives of its tax receivable agreement (TRA) holders have irrevocably waived the right to an Early Termination Payment tied to any change of control with a definitive merger agreement signed on or before December 31, 2026. The TRA will terminate upon consummation of such a qualifying change of control, while TRA holders keep their other rights, including tax benefit payments for prior and current years.
Waiver covers change-of-control transactions with a definitive merger agreement executed on or before December 31, 2026.
Upon consummation of a qualifying change of control, the TRA terminates under its terms.
TRA holders keep rights to tax benefit payments for taxable years ending before, with, or including the transaction.
The company says it is not a party to the waiver; the filing gives no dollar amounts.
Analog Devices agreed to acquire Alif Semiconductor, a maker of low-power microcontrollers and fusion processors with AI/ML acceleration, in an all-cash deal for $1.35 billion upfront plus up to $200 million in contingent consideration. The filing says the deal is expected to close in the fourth quarter of calendar 2026, subject to closing conditions and Hart-Scott-Rodino antitrust review, and both boards have approved it.
Upfront consideration: $1.35 billion in cash to Alif stockholders
Contingent consideration: up to $200 million additional payment
Expected close: fourth quarter of calendar 2026, subject to Hart-Scott-Rodino waiting period and customary conditions
Advisors: PJT Partners to ADI; Qatalyst Partners to Alif
Turn Therapeutics appointed Robert R. Redfield, M.D., former Director of the U.S. Centers for Disease Control and Prevention, as Chief Scientific Officer. The filing says he will contribute to the scientific and clinical strategy for GX-03 across several indications.
Robert R. Redfield, M.D., appointed Chief Scientific Officer, announced September 9, 2026
Redfield served as the 18th Director of the U.S. Centers for Disease Control and Prevention, from 2018 to 2021
GX-03 is being evaluated in atopic dermatitis and developed for onychomycosis, hidradenitis suppurativa, and potential additional indications
Stephen M. Hahn, M.D., former FDA Commissioner, is listed as Executive Clinical and Regulatory Lead
Ball Corporation's board elected Darlene Nicosia, CEO of Maker's Pride, and Sherry Buck, former CFO of W.L. Gore & Associates, as directors on September 8, 2026, effective September 21, 2026. The company said the two bring manufacturing, operations and finance experience to the board, and the filing discloses no financial results, guidance or deal terms.
Nicosia has been CEO of Maker's Pride since 2022 and previously held leadership roles at the Coca-Cola Company from 1993 to 2022.
Buck retired in December 2025 as CFO of W.L. Gore & Associates, a role she held from 2021, and has served on the Lennox International board since 2019.
Nicosia is expected to join the Finance and Nominating/Corporate Governance Committees; Buck is expected to join the Finance and Audit Committees.
The appointments were announced in a press release dated September 9, 2026, furnished as Exhibit 99.1.
Academy Sports and Outdoors reported second-quarter fiscal 2026 net sales of $1,647.3 million, up 3.0%, with comparable sales down 0.4%. The company raised its fiscal 2026 adjusted EPS guidance to $6.50 to $6.90 from $6.40 to $6.80, while keeping its sales guidance unchanged, which supports shareholders' expectations for earnings growth.
Q2 net sales of $1,647.3 million, up 3.0%; comparable sales fell 0.4%
Q2 adjusted diluted EPS of $2.31, up 19.1%; GAAP diluted EPS of $2.17, up 17.3%; net tariff refund benefit added $0.06 to EPS
Fiscal 2026 adjusted diluted EPS guidance raised to $6.50 to $6.90; sales guidance unchanged at $6,230 million to $6,355 million
Quarterly dividend of $0.15 per share, payable October 14, 2026, to holders of record on September 16, 2026
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.